The company holds a family of proprietary intellectual property and licensed technology from the Medical Research Council (UK) in the field of dermatology.

HS Pharma is committed to identifying, developing and commercializing innovative therapies to address significant unmet global dermatological needs.  


The company intends to utilize the form-dependent biological properties of our patented silicate technology to develop a potential range of highly effective topical therapeutic products targeting wound care and infectious diseases.